Form 4: Nurix Therapeutics Executive Gwenn Hansen Reports Stock Transactions

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• On April 30, 2024, Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, engaged in transactions involving the company's stock.
• Hansen acquired 3,206 shares of common stock and 2,000 shares of common stock at $0.
• Hansen disposed of 2,007 shares of common stock at a weighted average price of $12.0422 to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
• The sales were mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction.
• Following these transactions, Hansen directly owns 39,601 shares of common stock.
• Hansen also transacted with 3,206 and 2,000 Restricted Stock Units.
• Following these transactions, Hansen directly owns 22,448 and 16,000 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor the actions of those with privileged information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares to cover tax obligations, but the overall impact is likely minimal.

Key Dates